Delving into the Latest Updates on Tecogalan sodium with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

SP PG, Tecogalan sodium (USAN), DS 4152

+ [1]

Target-

Action

inhibitors

Mechanism

Angiogenesis inhibitors

Therapeutic Areas

NeoplasmsImmune System DiseasesInfectious Diseases+ [2]

Active Indication-

Inactive Indication

HIV InfectionsKaposi SarcomaSolid tumor

Originator Organization

Daiichi Sankyo Co., Ltd.

Active Organization-

Inactive Organization

Daiichi Pharmaceutical Co., Ltd.

National Cancer Institute

License Organization-

Drug Highest PhaseDiscontinuedPhase 1

First Approval Date-

Regulation-

Login to view timeline

The exact mechanisms of the angiostatic effect by tecogalan sodium (TS) remain unclear. We examined the effects of TS on in vitro angiogenic activity, proteolytic activity and proliferation of retinal vascular endothelial cells (RECs). TS markedly inhibited the in vitro angiogenic activity of RECs although the growth inhibition of RECs was small. TS apparently decreased the cell-associated urokinase-type plasminogen activator (uPA) activity and matrix metalloprotease 1 (MMP-1) activity even in the presence of anti-bFGF IgG. Thus, the suppression of the periendothelial matrix-degrading activities related to uPA and MMP-1 is suggested to be another possible mechanism of the antiangiogenic effect of TS, besides its prevention of bFGF REC binding which has previously been reported.

01 Nov 1997·Current opinion in oncologyQ3 · MEDICINE

Clinical trials of antiangiogenic agents

Q3 · MEDICINE

Review

Author: Przemyslaw Twardowski ; William J. Gradishar

Acquisition of new blood vessels is a required step in malignant transformation, tumor growth, and metastasis. Inhibition of angiogenesis is one of the most promising new strategies for the treatment of malignant neoplasms. In recent years, several antiangiogenic compounds, including TNP-470, matrix metalloproteinase inhibitors, carboxyamidotriazole, and tecogalan sodium, have entered clinical trials. In this we review, we look at the results of early clinical trials of these agents and discuss the new angiogenesis inhibitors in preclinical development.

01 Jul 1996·Annals of oncology : official journal of the European Society for Medical OncologyQ1 · MEDICINE

A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium

Q1 · MEDICINE

Article

Author: S. Fields ; L. Smetzer ; K. Sudo ; D. Rinaldi ; J.R. Eckardt ; H.A. Burris ; M. Rothenberg ; T. Oguma ; S.G. Eckhardt ; L. Higashi ; R. Atsumi ; D.D. Von Hoff ; G. Rodriguez ; G. Weiss ; R. Barrington ; K. Masuo ; J.G. Kuhn

BACKGROUND:

Tecogalan sodium is an angiogenesis inhibitor isolated from a sulfated polysaccharide produced by the bacterium Arthrobacter. The antiangiogenic effect of tecogalan sodium is thought to be mediated by the inhibition of binding of basic fibroblast growth factor to cellular receptors.

PATIENTS AND METHODS:

A phase I study was conducted in thirty-three patients with refractory malignancies, including AIDS-associated Kaposi's sarcoma. Patients received a single i.v. infusion every three weeks with the infusion duration ranging from one to twenty-four hours. Seven different dosage levels were studied (125, 185, 240, 300, 390, 445, and 500 mg/m2).

RESULTS:

The primary dose-limiting toxicity was prolongation of the activated partial thromboplastin time with peak times being between 1.0-4.0 times the upper limit of normal. This toxicity was ameliorated at a given dose level by prolonging the infusion time. Other common toxicities included fever (40%) and rigors (31%) which were well controlled with acetominophen and meperidine. The serum half-life of tecogalan sodium was between 1-1.5 hours and < 25% of unchanged drug was excreted in the urine.

CONCLUSIONS:

The recommended phase II dose of tecogalan sodium on this schedule is 390 mg/m2 over 24 hours. Other schedules including continuous administration should be investigated to maximize the efficacy of this novel angiogenesis inhibitor.

100 Deals associated with Tecogalan sodium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D06052	-	-	-

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	Phase 1	United States	Daiichi Pharmaceutical Co., Ltd.	31 Aug 2001
Kaposi Sarcoma	Phase 1	United States	Daiichi Pharmaceutical Co., Ltd.	31 Aug 2001
Solid tumor	Phase 1	European Union	-	-
Solid tumor	Phase 1	Japan	Daiichi Pharmaceutical Co., Ltd.	-